Stay updated with breaking news from Analytical Reference Standards. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
ChromaDex (NASDAQ:CDXC – Get Rating) had its price objective cut by stock analysts at HC Wainwright from $8.00 to $7.00 in a note issued to investors on Tuesday, The Fly reports. HC Wainwright’s price target indicates a potential upside of 266.49% from the stock’s current price. CDXC has been the topic of several other research […]
Brokerages expect ChromaDex Co. (NASDAQ:CDXC – Get Rating) to announce sales of $18.87 million for the current quarter, according to Zacks Investment Research. Four analysts have provided estimates for ChromaDex’s earnings, with the highest sales estimate coming in at $21.00 million and the lowest estimate coming in at $16.07 million. ChromaDex posted sales of $17.70 […]
Mind Medicine (MindMed) (NASDAQ:MNMD – Get Rating) and ChromaDex (NASDAQ:CDXC – Get Rating) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their profitability, valuation, dividends, earnings, analyst recommendations, institutional ownership and risk. Analyst Recommendations This is a breakdown of current recommendations […]
Zacks Investment Research upgraded shares of ChromaDex (NASDAQ:CDXC – Get Rating) from a sell rating to a hold rating in a research report report published on Wednesday, Zacks.com reports. According to Zacks, “ChromaDex Corporation and its subsidiaries supply phytochemical reference standards and reference materials, related contract services, and products for the dietary supplement, nutraceutical, food […]
ChromaDex Co. (NASDAQ:CDXC – Get Rating) saw a significant increase in short interest in the month of April. As of April 30th, there was short interest totalling 3,440,000 shares, an increase of 27.4% from the April 15th total of 2,700,000 shares. Currently, 8.9% of the company’s stock are short sold. Based on an average daily […]